In the current study, we demonstrated that the TIMP1 protein levels in BM plasma (BM microenvironment) and the TIMP1 mRNA expression in malignant plasma cells from patients with MM (myeloma cells) were higher than those in patients with MGUS. This evidence concerns the gene TIMP1 and Miyoshi myopathy.